NOVO NORDISK A/S Bagsværd, Denmark, 20 November 2019 - Novo Nordisk is today hosting a Capital Markets Day where the company is introducing its strategic aspirations.
Based on the latest financial guidance provided in connection with the financial report for the first nine months of 2019, Novo Nordisk is on track to meet its current long-term financial targets comprising average operating profit growth of 5%, cash-to-earnings of 85% (3-year average) and operating profit after tax over net operating assets (OPAT/NOA) of 80%.
To reflect the broad growth aspects of Novo Nordisk across therapy areas and geographies, the current approach to long-term financial targets focusing on specific financial aspects is no longer sufficiently describing Novo Nordisk’s future growth outlook. Consequently, Novo Nordisk is replacing the current long-term financial targets structure with a more comprehensive approach describing the future growth aspirations of the company under the headline: strategic aspirations for 2025.
The strategic aspirations reflecting the sustained growth opportunities until 2025 are intended to cover future growth drivers of Novo Nordisk and thereby providing investors with an understanding of Novo Nordisk’s growth and investment opportunities across therapy areas and geographies.
The strategic aspirations are based on four dimensions:
Purpose and sustainability: Novo Nordisk is a company with a clear purpose and with the aspiration to be respected for adding value to society.
Innovation: Novo Nordisk has a clear therapeutic focus and aspiration to bring innovative treatment to people with serious chronic diseases.
Commercial execution: Novo Nordisk sees solid growth opportunities across therapeutic areas and geographies with its broad product portfolio and market-fit approach.
Financial outlook: Novo Nordisk is driving operational efficiencies and expects solid sales and operating profit growth leading to attractive capital allocation to shareholders.
Throughout today’s presentations, Novo Nordisk is presenting the strategic aspirations for the four dimensions, which reflect the aspirations across therapy areas and commercial units. During the day, based on the Novo Nordisk corporate strategy, senior management presentations are covering the therapeutic areas: Diabetes, Obesity, Biopharm and Other serious chronic diseases as well as all commercial regions including North America Operations and the five regions in International Operations. In addition, Novo Nordisk’s approaches to innovation, product supply and financials are presented.
“Novo Nordisk is on track to meet its current long-term financial targets, and we have therefore decided to introduce our new strategic aspirations covering the future growth opportunities,” said Lars Fruergaard Jørgensen, CEO of Novo Nordisk. “We believe the future growth opportunities for Novo Nordisk are very promising and with the introduction of the strategic aspirations, we are now providing a more comprehensive approach to describe our growth drivers.”
All main sessions of the Capital Markets Day 2019 are webcast live, and a replay will be made available on the investor section of novonordisk.com. Presentation material for the Capital Markets Day 2019 will be also available throughout the day on the investor section of novonordisk.com.
Further information
| Media: | ||
| Mette Kruse Danielsen | +45 4442 3883 | mkd@novonordisk.com |
| Ken Inchausti (US) | +1 609 240 9429 | kiau@novonordisk.com |
| Investors: | ||
| Peter Hugreffe Ankersen | +45 3075 9085 | phak@novonordisk.com |
| Valdemar Borum Svarrer | +45 3079 0301 | jvls@novonordisk.com |
| Ann Søndermølle Rendbæk | +45 3075 2253 | arnd@novonordisk.com |
| Mark Joseph Root | +45 3079 4211 | mjhr@novonordisk.com |
| Kristoffer Due Berg (US) | +1 609 235 2989 | krdb@novonordisk.com |
Company announcement No 70 / 2019
Attachment
- PR1911120_CMD2019
